Orphazyme to prepare for filing of arimoclomol in US for Niemann-Pick disease Type C (NPC)
July 21, 2019 06:03 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 18/2019Company Registration No. 32266355 ...
Orphazyme completes enrollment in phase 3 trial evaluating arimoclomol in Amyotrophic Lateral Sclerosis
July 18, 2019 01:00 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 17/2019 ...
Orphazyme to prepare for filing of arimoclomol in Europe for Niemann-Pick disease Type C (NPC)
June 07, 2019 00:56 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Orphazyme’s Phase II/III trial in sporadic Inclusion Body Myositis fully enrolled
April 23, 2019 06:39 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 13/2019 ...
Publication of manuscript on preclinical Proof-of-Concept of arimoclomol in Gaucher disease
November 27, 2018 08:51 ET
|
ORPHAZYME A/S
Orphazyme A/SInvestor news No....
Orphazyme reports encouraging arimoclomol clinical trial top-line data in Niemann-Pick disease Type C (NPC)
September 28, 2018 01:00 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Orphazyme to Present at 25th NPUK Annual Family Conference 2018
September 20, 2018 09:19 ET
|
ORPHAZYME A/S
Orphazyme A/SInvestor news No....
Orphazyme announces enrollment of first patient in Phase III clinical trial of arimoclomol for ALS
August 10, 2018 12:19 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Publication of manuscript related to Phase II trial results for arimoclomol in patients with SOD1 ALS
January 24, 2018 16:06 ET
|
ORPHAZYME A/S
Investor newsOrphazyme A/SNo. 01/2018 ...